Let's Play PET References - "M"

[Back to Menu] [Back to Index]
  • MacGregor, R, Fowler, J, Wolf, A: Synthesis of suicide inhibitors of monoamine oxidase: Carbon-11 labeled clorgyline, L-deprenyl and D-deprenyl. J. Label Cmpds. Radiopharm., 25:1-9, 1988.

  • Macke, H, Smithjones, P, Maina, T, Stolz, B, Albert, R, Bruns, C, Reist, H. New octreotide derivatives for invivo targeting of somatostatin receptor-positive tumors for single photon emission computed tomography (SPECT) and positron emission tomography (PET). Horm Metab Res, 27(Suppl): 12-17, 1993.

  • Madsen, P, Holm, S, Vorstrup, S, Friberg, L, Lassen, N, Wildschiodtz, G: Human regional cerebral blood flow during rapid-eye movement sleep. J Cereb Blood Flow Metab, 11:502-507, 1991.

  • Madsen S, Welch M, Motekaitis R, Martell A. 68GaTHM2BED: a potential generator-produced tracer of myocardial perfusion for positron emission tomography. Int J Radiat Appl Instr B Nucl Med Biol, 19:431-44, 1992.

  • Mann, DMA, The neuropathology of Alzheimer's disease: A review with pathogenic, aetiological and therapeutic considerations. Mech. Ageing Develop., 31:213-255, 1985.

  • Markham J; Schuster J. Effects of nonideal input functions on PET measurements of pulmonary blood flow. J Appl Physiol, 1992, 72:2495-500.

  • Marshall, R, Tillisch, J, Phelps, M, Huang, SC, Carson, R, Henze, E, et al.: Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation , 67:766-778, 1983.

  • Martin GV; Caldwell J; Graham M; Grierson J; Kroll K; Cowan M; Lewellen T; Rasey J; Casciari J; Krohn K. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med, 1992, 33:2202-8.

  • Maziere B, Coenen H, Halldin C, Nagren K, Pike V. PET radioligands for dopamine receptors and re-uptake sites: chemistry and biochemistry. Int J Radiat Appl Instr B Nucl Med Biol, 19:497-512, 1992.

  • Maziere M; Khalili-Varasteh M; Delforge J; Janier M; Leguludec D; Prenant C; Syrota A. Positron emission tomography and cholinergic mechanisms: an overview. Prog Brain Res, 1990, 84:347-59.

  • Mazire, B & Mazire, M: Positron emission tomography studies of brain receptors, Fundam Clin Pharmacol, 5:61-91, 1991.

  • Mazziotta, J. Huntington's disease: Studies with structural imaging techniques and positron emission tomography. Semin Neurol, 9:360-9, 1989.

  • Mazziotta, JC: Human cerebral metabolism: studies in normal subjects and patients with dementia and amnesia. Ann NY Acad Sci, 444:269-286, 1985.

  • Mazziotta, J, Gilman, S., Eds. Clinical Brain Imaging: Principles and Applications. Davis, Philadelphia, 1992.

  • Mazziotta, J, Phelps, M, Carson, R, Kuhl, D: Tomographic mapping of human cerebral metabolism: Auditory stimulation. Neurology, 32:921-36, 1982.

  • McGeer, P, Kamo, H, Harrop, R, et al., Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease. Neurology, 36:1569-74, 1986.

  • McGeer, PL, Kamo, H, Harrop, R, et al., Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. Can. Med. Assoc. 134:597-607, 1986.

  • McKee, AC, Kosik, KS, Kowall, NW. Neuritic pathology and dementia in Alzheimer's disease. Ann. Neurol., 30:156-165, 1991.

  • Meikle, SR, Dahlbom, M, Cherry, SR: Attenuation correction using count-limited transmission data in positron emission tomography. J Nucl Med, 34:143-144, 1993.

  • Melega W, Grafton S, Huang S, Satyamurthy N, Phelps M, Barrio J. L-6-[18F]fluoro-dopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography. J Cereb Blood Flow Metab, 11:890-7, 1991.

  • Melega W, Perlmutter M, Luxen A, Nissenson C, Grafton S, et al. 4 - [18F]fluoro - L - m-tyrosine: an L-3,4-dihydroxyphenylalanine analog for probing presynaptic dopaminergic function with positron emission tomography. J Neurochem, 53:311-4, 1989.

  • Merhige M; Garza D; Sease D; Rowe R; Tewson T; Emran A; Bolomey L; Gould K. Quantitation of the critically ischemic zone at risk during acute coronary occlusion using PET. J Nucl Med, 1991, 32:1581-6.

  • Mineura, K, Yashuda, T, Kowada, M, et al: PET evaluation of histologic malignancy in gliomas using oxygen-15 and fluorine-18-fluorodeoxyglucose. Neurolog Res, 8:164-168, 1986.

  • Minn H; Paul R. Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future [editorial]. Eur J Nucl Med, 1992, 19:921-4.

  • Minn, H, Paul, R, Ahonen, A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med, 29:1521-1525, 1988.

  • Mintun, M, Raichle, M, Kilbourn, M, Wooten, G, Welch, M: A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol,15:217-27, 1984.

  • Muhr C; Bergstrom M. Positron emission tomography applied in the study of pituitary adenomas. J Endocrinol Invest, 1991, 14:509-28.

  • Mulholland, G, Sugimoto, H, Jewett, D, Kilbourn, M: Simple preparation of a novel C-11 acetylcholinesterase inhibitor. J Nucl Med, 30:822, 1989.

  • Muzik, O, Beanlands, R, Hutchins, G, Mangner, T, Nguyen, N, Schwaiger, M: Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med, 34:83-91, 1993.

  • Muzik, O, Beanlands, R, Wolfe, E, Hutchins, G, Schwaiger, M: Automated region definition for cardiac nitrogen-13-ammonia PET imaging. J Nucl Med, 34:336-344, 1993.

  • Myers, EM, Leffall, LD. Head and neck oncology: Diagnosis, treatment and rehabilitation. Little, Brown and Company, 1991.

    Let's Play PET, Copyright 1992, 1993 Regents of the University of California
    All Rights Reserved

    [Back to Menu] [Back to Index]